메뉴 건너뛰기




Volumn 9, Issue 3, 2012, Pages 273-286

S-1 as a core anticancer fluoropyrimidine agent

Author keywords

5 fluorouracil prodrug; Alternate day administration; Orally administrable fluoropyrimidines; S 1

Indexed keywords

ALPHA FLUORO BETA ALANINE; CAPECITABINE; CISPLATIN; CYTOCHROME P450 2A6; DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OTERACIL POTASSIUM; OXIDOREDUCTASE INHIBITOR; RO 0094889; TEGAFUR; UFT; UNCLASSIFIED DRUG;

EID: 84857608031     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.652945     Document Type: Review
Times cited : (28)

References (90)
  • 1
    • 77951755278 scopus 로고    scopus 로고
    • Pancreatic cancer
    • Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17
    • (2010) N Engl J Med , vol.362 , pp. 1605-1617
    • Hidalgo, M.1
  • 2
    • 79951646505 scopus 로고    scopus 로고
    • Pharmacotherapy for pediatric soft-tissue sarcomas
    • Casanova M, Ferrari A. Pharmacotherapy for pediatric soft-tissue sarcomas. Expert Opin Pharmacother 2011;12:517-31
    • (2011) Expert Opin Pharmacother , vol.12 , pp. 517-531
    • Casanova, M.1    Ferrari, A.2
  • 4
    • 33745464490 scopus 로고
    • Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
    • Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957;179:663-6
    • (1957) Nature , vol.179 , pp. 663-666
    • Heidelberger, C.1    Chaudhuri, N.K.2    Danneberg, P.3
  • 5
    • 0014151383 scopus 로고
    • Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells
    • Wilkoff LJ, Wilcox WS, Burdeshaw JA, et al. Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells. J Natl Cancer Inst 1967;39:965-75
    • (1967) J Natl Cancer Inst , vol.39 , pp. 965-975
    • Wilkoff, L.J.1    Wilcox, W.S.2    Burdeshaw, J.A.3
  • 6
    • 78651156947 scopus 로고
    • Experimental evaluation of potential anticancer agents. XIII. on the criteria and kinetics associated with "curability" of experimental leukemia
    • Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964;35:1-111
    • (1964) Cancer Chemother Rep , vol.35 , pp. 1-111
    • Skipper, H.E.1    Schabel Jr., F.M.2    Wilcox, W.S.3
  • 7
    • 0024539308 scopus 로고
    • A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
    • Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32 (Pubitemid 19098135)
    • (1989) Journal of Clinical Oncology , vol.7 , Issue.4 , pp. 425-432
    • Lokich, J.J.1    Ahlgren, J.D.2    Gullo, J.J.3    Philips, J.A.4    Fryer, J.G.5
  • 8
    • 0344109583 scopus 로고    scopus 로고
    • Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
    • Meta-analysis Group in Cancer
    • Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8
    • (1998) J Clin Oncol , vol.16 , pp. 301-308
  • 10
    • 65449119562 scopus 로고    scopus 로고
    • Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002)
    • Kinoshita T, Sasako M, Sano T, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer 2009;12:37-42
    • (2009) Gastric Cancer , vol.12 , pp. 37-42
    • Kinoshita, T.1    Sasako, M.2    Sano, T.3
  • 11
    • 77949545583 scopus 로고    scopus 로고
    • Phase II study of preoperative concurrent chemoradiation therapy with S-1 in patients with T4 oral squamous cell carcinoma
    • Nomura T, Murakami R, Toya R, et al. Phase II study of preoperative concurrent chemoradiation therapy with S-1 in patients with T4 oral squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010;76:1347-52
    • Int J Radiat Oncol Biol Phys , vol.2010 , Issue.76 , pp. 1347-1352
    • Nomura, T.1    Murakami, R.2    Toya, R.3
  • 12
    • 73449122261 scopus 로고    scopus 로고
    • Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma
    • Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 2009;250:950-6
    • (2009) Ann Surg , vol.250 , pp. 950-956
    • Murakami, Y.1    Uemura, K.2    Sudo, T.3
  • 14
    • 66149153449 scopus 로고    scopus 로고
    • Advancements in the management of pancreatic cancer
    • Li J, Saif MW. Advancements in the management of pancreatic cancer. JOP 2009;10:109-17
    • (2009) JOP , vol.10 , pp. 109-117
    • Li, J.1    Saif, M.W.2
  • 15
    • 2142776273 scopus 로고
    • The catabolism of uracil in vivo and in vitro
    • Rutman RJ, Cantarow A, Paschkis KE. The catabolism of uracil in vivo and in vitro. J Biol Chem 1954;210:321-9
    • (1954) J Biol Chem , vol.210 , pp. 321-329
    • Rutman, R.J.1    Cantarow, A.2    Paschkis, K.E.3
  • 16
    • 58149155550 scopus 로고
    • Microbial studies of 6-azauracil, an antagonist of uracil
    • Handschumacher RE, Welch AD. Microbial studies of 6-azauracil, an antagonist of uracil. Cancer Res 1956;16:965-9
    • (1956) Cancer Res , vol.16 , pp. 965-969
    • Handschumacher, R.E.1    Welch, A.D.2
  • 17
    • 0011234930 scopus 로고
    • Studies on fluorinated pyrimidines. II. Effects on transplanted tumors
    • Heidelberger C, Griesbach L, Montag BJ, et al. Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. Cancer Res 1958;18:305-17
    • (1958) Cancer Res , vol.18 , pp. 305-317
    • Heidelberger, C.1    Griesbach, L.2    Montag, B.J.3
  • 18
    • 0000711089 scopus 로고
    • Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo
    • Chaudhuri NK, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic- 2-C14 acid in vivo. Cancer Res 1958;18:318-28
    • (1958) Cancer Res , vol.18 , pp. 318-28
    • Chaudhuri, N.K.1    Montag, B.J.2    Heidelberger, C.3
  • 19
    • 66849099602 scopus 로고    scopus 로고
    • XIII international charles heidelberger symposium and 50 years of fluoropyrimidines in cancer therapy held on September 6 to 8 2007 at New York University Cancer Institute, Smilow Conference Center
    • Muggia FM, Peters GJ, Landolph JR Jr. XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther 2009;8:992-9
    • (2009) Mol Cancer Ther , vol.8 , pp. 992-999
    • Muggia, F.M.1    Peters, G.J.2    Landolph Jr., J.R.3
  • 20
    • 0000875305 scopus 로고
    • Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase
    • Hartmann KU, Heidelberger C. Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. J Biol Chem 1961;236:3006-13
    • (1961) J Biol Chem , vol.236 , pp. 3006-3013
    • Hartmann, K.U.1    Heidelberger, C.2
  • 21
    • 0000741537 scopus 로고
    • Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo
    • Danneberg PB, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo. Cancer Res 1958;18:329-34
    • (1958) Cancer Res , vol.18 , pp. 329-334
    • Danneberg, P.B.1    Montag, B.J.2    Heidelberger, C.3
  • 22
    • 0020056302 scopus 로고
    • In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas
    • Spears CP, Shahinian AH, Moran RG, et al. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-6 (Pubitemid 12173578)
    • (1982) Cancer Research , vol.42 , Issue.2 , pp. 450-456
    • Spears, C.P.1    Shahinian, A.H.2    Moran, R.G.3
  • 24
    • 0023187085 scopus 로고
    • Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
    • Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47:2203-6 (Pubitemid 17074634)
    • (1987) Cancer Research , vol.47 , Issue.8 , pp. 2203-2206
    • Heggie, G.D.1    Sommadossi, J.-P.2    Cross, D.S.3
  • 25
    • 0020353668 scopus 로고
    • High-dose 5-fluorouracil with delayed uridine 'rescue' in mice
    • Martin DS, Stolfi RL, Sawyer RC, et al. High-dose 5-fluorouracil with delayed uridine "rescue" in mice. Cancer Res 1982;42:3964-70 (Pubitemid 13198549)
    • (1982) Cancer Research , vol.42 , Issue.10 , pp. 3964-3970
    • Martin, D.S.1    Stolfi, R.L.2    Sawyer, R.C.3
  • 26
    • 50949097255 scopus 로고    scopus 로고
    • RNA-based 5-fluorouracil toxicity requires the pseudouridylation activity of Cbf5p
    • Hoskins J, Butler JS. RNA-based 5-fluorouracil toxicity requires the pseudouridylation activity of Cbf5p. Genetics 2008;179:323-30
    • (2008) Genetics , vol.179 , pp. 323-330
    • Hoskins, J.1    Butler, J.S.2
  • 27
    • 0021331040 scopus 로고
    • 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity
    • Schuetz JD, Wallace HJ, Diasio RB. 5-Fluorouracil, inc. into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res 1984;44:1358-63 (Pubitemid 14174446)
    • (1984) Cancer Research , vol.44 , Issue.4 , pp. 1358-1363
    • Schuetz, J.D.1    Wallace, H.J.2    Diasio, R.B.3
  • 28
    • 0018744377 scopus 로고
    • Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine
    • Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res 1979;39:2406-13 (Pubitemid 9203429)
    • (1979) Cancer Research , vol.39 , Issue.7 , pp. 2406-2413
    • Houghton, J.A.1    Houghton, P.J.2    Wooten, R.S.3
  • 30
    • 0014834207 scopus 로고
    • Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate
    • Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 1970;23:155-60
    • (1970) Arch Neurol , vol.23 , pp. 155-160
    • Koenig, H.1    Patel, A.2
  • 32
    • 0028609605 scopus 로고
    • Complications and failures of subclavian-vein catheterization
    • Mansfield PF, Hohn DC, Fornage BD, et al. Complications and failures of subclavian-vein catheterization. N Engl J Med 1994;331:1735-8
    • (1994) N Engl J Med , vol.331 , pp. 1735-1738
    • Mansfield, P.F.1    Hohn, D.C.2    Fornage, B.D.3
  • 33
    • 33645718977 scopus 로고    scopus 로고
    • Therapy insight: Venous-catheter-related thrombosis in cancer patients
    • Agnelli G, Verso M. Therapy Insight: venous-catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 2006;3:214-22
    • (2006) Nat Clin Pract Oncol , vol.3 , pp. 214-222
    • Agnelli, G.1    Verso, M.2
  • 34
    • 0141993698 scopus 로고    scopus 로고
    • A Cost Comparison of Oral Tegafur Plus Uracil/Folinic Acid and Parenteral Fluorouracil for Colorectal Cancer in Canada
    • DOI 10.2165/00019053-200321140-00004
    • Maroun J, Asche C, Romeyer F, et al. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 2003;21:1039-51 (Pubitemid 37255457)
    • (2003) PharmacoEconomics , vol.21 , Issue.14 , pp. 1039-1051
    • Maroun, J.A.1    Asche, C.2    Romeyer, F.3    Mukherjee, J.4    Cripps, C.5    Oza, A.6    Skillings, J.R.7    Letarte, J.8
  • 35
    • 85044700692 scopus 로고    scopus 로고
    • Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: Systematic review and economic evaluation
    • Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003;7:1-93
    • (2003) Health Technol Assess , vol.7 , pp. 1-93
    • Ward, S.1    Kaltenthaler, E.2    Cowan, J.3    Brewer, N.4
  • 36
    • 0031017851 scopus 로고    scopus 로고
    • Patient preferences for oral versus intravenous palliative chemotherapy
    • Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-15 (Pubitemid 27021524)
    • (1997) Journal of Clinical Oncology , vol.15 , Issue.1 , pp. 110-115
    • Liu, G.1    Franssen, E.2    Fitch, M.I.3    Warner, E.4
  • 39
    • 53049092394 scopus 로고    scopus 로고
    • Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study
    • Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008;19:1720-6
    • (2008) Ann Oncol , vol.19 , pp. 1720-1726
    • Rothenberg, M.L.1    Cox, J.V.2    Butts, C.3
  • 40
    • 73349085566 scopus 로고    scopus 로고
    • ML17032 trial: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
    • Ryu MH, Kang YK. ML17032 trial: capecitabine/cisplatin versus 5- fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. Expert Rev Anticancer Ther 2009;9:1745-51
    • (2009) Expert Rev Anticancer Ther , vol.9 , pp. 1745-1751
    • Ryu, M.H.1    Kang, Y.K.2
  • 41
    • 63749118193 scopus 로고    scopus 로고
    • Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial
    • Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5- fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-73
    • (2009) Ann Oncol , vol.20 , pp. 666-673
    • Kang, Y.K.1    Kang, W.K.2    Shin, D.B.3
  • 42
    • 77951888102 scopus 로고    scopus 로고
    • Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial
    • Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28:1547-53
    • (2010) J Clin Oncol , vol.28 , pp. 1547-1553
    • Ajani, J.A.1    Rodriguez, W.2    Bodoky, G.3
  • 43
    • 77956150646 scopus 로고    scopus 로고
    • Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: A randomised phase 2/ 3 non-inferiority study (FIRIS study)
    • Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/ 3 non-inferiority study (FIRIS study). Lancet Oncol 2010;11:853-60
    • (2010) Lancet Oncol , vol.11 , pp. 853-860
    • Muro, K.1    Boku, N.2    Shimada, Y.3
  • 46
    • 0014200274 scopus 로고
    • Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolities. Article in Russian
    • Giller SA, Zhuk RA, Lidak MIu. Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolities. Article in Russian. Dokl Akad Nauka SSSR 1967;176:332-5
    • (1967) Dokl Akad Nauka SSSR , vol.176 , pp. 332-335
    • Giller, S.A.1    Zhuk, R.A.2    Lidak, M.Iu.3
  • 47
    • 0017764250 scopus 로고
    • Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer
    • Buroker T, Miller A, Baker L, et al. Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer. Cancer Treat Rep 1977;61:1579-80 (Pubitemid 8241631)
    • (1977) Cancer Treatment Reports , vol.61 , Issue.8 , pp. 1579-1580
    • Buroker, T.1    Miller, A.2    Baker, L.3
  • 48
    • 0029996291 scopus 로고    scopus 로고
    • Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations
    • Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996;26:395-403 (Pubitemid 26150089)
    • (1996) Xenobiotica , vol.26 , Issue.4 , pp. 395-403
    • Shimada, T.1    Yamazaki, H.2    Guengerich, F.P.3
  • 49
    • 58149383761 scopus 로고    scopus 로고
    • Development history and concept of an oral anticancer agent S-1 (TS-1): Its clinical usefulness and future vistas
    • Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009;39:2-15
    • (2009) Jpn J Clin Oncol , vol.39 , pp. 2-15
    • Shirasaka, T.1
  • 50
    • 0018216763 scopus 로고
    • Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil
    • Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)- 5-fluorouracil. Gann 1978;69:763-72 (Pubitemid 9081584)
    • (1978) Gann, The Japanese Journal of Cancer Research , vol.69 , Issue.6 , pp. 763-772
    • Fujii, S.1    Ikenaka, K.2    Fukushima, M.3    Shirasaka, T.4
  • 51
    • 0018757734 scopus 로고
    • Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents
    • Fujii S, Kitano S, Ikenaka K, et al. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5- fluorouracil and level of 5-fluorouracil in rodents. Gann 1979;70:209-14 (Pubitemid 9184704)
    • (1979) Gann, The Japanese Journal of Cancer Research , vol.70 , Issue.2 , pp. 209-214
    • Fujii, S.1    Kitano, S.2    Ikenaka, K.3    Shirasaka, T.4
  • 52
    • 0018576207 scopus 로고
    • Fluorinated pyrimidine nucleosides. III. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides
    • DOI 10.1021/jm00197a010
    • Cook AF, Holman MJ, Kramer MJ, Trown PW. Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5- fluoropyrimidine nucleosides. J Med Chem 1979;22:1330-5 (Pubitemid 10193598)
    • (1979) Journal of Medicinal Chemistry , vol.22 , Issue.11 , pp. 1330-1335
    • Cook, A.F.1    Holman, M.J.2    Kramer, M.J.3    Trown, P.W.4
  • 54
    • 0032401829 scopus 로고    scopus 로고
    • Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors
    • Liu M, Cao D, Russell R, et al. Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res 1998;58:5418-24 (Pubitemid 28551125)
    • (1998) Cancer Research , vol.58 , Issue.23 , pp. 5418-5424
    • Liu, M.1    Cao, D.2    Russell, R.3    Handschumacher, R.E.4    Pizzorno, G.5
  • 55
  • 56
    • 0032127244 scopus 로고    scopus 로고
    • Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5 fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
    • DOI 10.1016/S0959-8049(98)00058-6, PII S0959804998000586
    • Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81 (Pubitemid 28342121)
    • (1998) European Journal of Cancer , vol.34 , Issue.8 , pp. 1274-1281
    • Miwa, M.1    Ura, M.2    Nishida, M.3    Sawada, N.4    Ishikawa, T.5    Mori, K.6    Shimma, N.7    Umeda, I.8    Ishitsuka, H.9
  • 58
    • 79952321958 scopus 로고    scopus 로고
    • Capecitabine and hand-foot syndrome
    • Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 2011;10:159-69
    • Expert Opin Drug Saf , vol.2011 , Issue.10 , pp. 159-169
    • Saif, M.W.1
  • 61
    • 0029835349 scopus 로고    scopus 로고
    • Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
    • Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57 (Pubitemid 26276346)
    • (1996) Anti-Cancer Drugs , vol.7 , Issue.5 , pp. 548-557
    • Shirasaka, T.1    Shimamato, Y.2    Ohshimo, H.3    Yamaguchi, M.4    Kato, T.5    Yonekura, K.6    Fukushima, M.7
  • 62
    • 0023250474 scopus 로고
    • Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts
    • Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987;78:748-55 (Pubitemid 17132408)
    • (1987) Japanese Journal of Cancer Research , vol.78 , Issue.7 , pp. 748-755
    • Tatsumi, K.1    Fukushima, M.2    Shirasaka, T.3    Fujii, S.4
  • 63
    • 0027227591 scopus 로고
    • Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats
    • Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-9 (Pubitemid 23267702)
    • (1993) Cancer Research , vol.53 , Issue.17 , pp. 4004-4009
    • Shirasaka, T.1    Shimamoto, Y.2    Fukushima, M.3
  • 64
    • 0000455889 scopus 로고
    • Investigations with 5-azaorotic acid an inhibitor of the biosynthesis of pyrimidines de novo
    • Granat P, Creasey WA, Calabresi P, Handschumacher RE. Investigations with 5-azaorotic acid, an inhibitor of the biosynthesis of pyrimidines de novo. Clin Pharmacol Ther 1965;6:436-47
    • (1965) Clin Pharmacol Ther , vol.6 , pp. 436-447
    • Granat, P.1    Creasey, W.A.2    Calabresi, P.3    Handschumacher, R.E.4
  • 67
    • 40749087276 scopus 로고    scopus 로고
    • Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
    • DOI 10.1158/1078-0432.CCR-07-1225
    • Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008;14:8-13 (Pubitemid 351377972)
    • (2008) Clinical Cancer Research , vol.14 , Issue.1 , pp. 8-13
    • Yen-Revollo, J.L.1    Goldberg, R.M.2    McLeod, H.L.3
  • 68
    • 33646469073 scopus 로고    scopus 로고
    • Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil
    • Yamashita T, Ueda Y, Fuji N, et al. Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil. Cancer Chemother Pharmacol 2006;58:183-8
    • (2006) Cancer Chemother Pharmacol , vol.58 , pp. 183-188
    • Yamashita, T.1    Ueda, Y.2    Fuji, N.3
  • 69
    • 33645981893 scopus 로고    scopus 로고
    • 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): Toxicity reduction and increased antitumor activity in mice
    • Saif MW, von Borstel R. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. Cancer Chemother Pharmacol 2006;58:136-42
    • (2006) Cancer Chemother Pharmacol , vol.58 , pp. 136-142
    • Saif, M.W.1    Von Borstel, R.2
  • 70
    • 40749153540 scopus 로고    scopus 로고
    • S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial
    • Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21
    • (2008) Lancet Oncol , vol.9 , pp. 215-221
    • Koizumi, W.1    Narahara, H.2    Hara, T.3
  • 71
    • 71249128928 scopus 로고    scopus 로고
    • Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study
    • Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-9
    • (2009) Lancet Oncol , vol.10 , pp. 1063-1069
    • Boku, N.1    Yamamoto, S.2    Fukuda, H.3
  • 72
    • 79953025190 scopus 로고    scopus 로고
    • Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
    • Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011;14:72-80
    • Gastric Cancer , vol.2011 , Issue.14 , pp. 72-80
    • Narahara, H.1    Iishi, H.2    Imamura, H.3
  • 73
    • 77954922535 scopus 로고    scopus 로고
    • First-line treatment of patients with metastatic pancreatic cancer: Results of a Phase II trial with S-1 (CESAR-Study group)
    • Strumberg D, Bergmann L, Graeven U, et al. First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group). Int J Clin Pharmacol Ther 2010;48:470-2
    • Int J Clin Pharmacol Ther , vol.2010 , Issue.48 , pp. 470-472
    • Strumberg, D.1    Bergmann, L.2    Graeven, U.3
  • 77
    • 79952082092 scopus 로고    scopus 로고
    • Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
    • Chuah B, Goh BC, Lee SC, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 2011;102:478-83
    • (2011) Cancer Sci , vol.102 , pp. 478-483
    • Chuah, B.1    Goh, B.C.2    Lee, S.C.3
  • 79
    • 84859756288 scopus 로고    scopus 로고
    • Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors
    • Epub ahead of print
    • Scheulen ME, Saito K, Hilger RA, et al. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; [Epub ahead of print]
    • (2011) Cancer Chemother Pharmacol
    • Scheulen, M.E.1    Saito, K.2    Hilger, R.A.3
  • 80
    • 0000508052 scopus 로고
    • Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum
    • Lipkin M, Sherlock P, Bell B. Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum. Gastroenterology 1963;45:721-9
    • (1963) Gastroenterology , vol.45 , pp. 721-729
    • Lipkin, M.1    Sherlock, P.2    Bell, B.3
  • 81
    • 0000850597 scopus 로고
    • Kinetics of proliferation of cancer cells in neoplastic effusions in man
    • Clarkson B, Ota K, Ohkita T, et al. Kinetics of proliferation of cancer cells in neoplastic effusions in man. Cancer 1965;18:1189-213
    • (1965) Cancer , vol.18 , pp. 1189-213
    • Clarkson, B.1    Ota, K.2    Ohkita, T.3
  • 84
    • 57849165882 scopus 로고    scopus 로고
    • Comparison of alternate-day versus consecutive-day treatment with S-1: Assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo
    • Arai W, Hosoya Y, Haruta H, et al. Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo. Int J Clin Oncol 2008;13:515-20
    • (2008) Int J Clin Oncol , vol.13 , pp. 515-520
    • Arai, W.1    Hosoya, Y.2    Haruta, H.3
  • 85
    • 77950961920 scopus 로고    scopus 로고
    • Alternate-day treatment with S-1 in patients with gastric cancer: A retrospective study of strategies for reducing toxicity
    • Sakuma K, Hosoya Y, Arai W, et al. Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity. Int J Clin Oncol 2010;15:166-71
    • Int J Clin Oncol , vol.2010 , Issue.15 , pp. 166-171
    • Sakuma, K.1    Hosoya, Y.2    Arai, W.3
  • 86
    • 77954361284 scopus 로고    scopus 로고
    • Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer
    • Hirose T, Fujita K, Nishimura K, et al. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. Oncol Rep 2010;24:529-36
    • (2010) Oncol Rep , vol.24 , pp. 529-536
    • Hirose, T.1    Fujita, K.2    Nishimura, K.3
  • 87
    • 79951609864 scopus 로고    scopus 로고
    • Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: Influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
    • Kim KP, Jang G, Hong YS, et al. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br J Cancer 2011;104:605-12
    • Br J Cancer , vol.2011 , Issue.104 , pp. 605-612
    • Kim, K.P.1    Jang, G.2    Hong, Y.S.3
  • 88
    • 79251549824 scopus 로고    scopus 로고
    • Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: A prospective study
    • Tsunoda A, Nakao K, Watanabe M, et al. Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. Ann Oncol 2011;22:355-61
    • (2011) Ann Oncol , vol.22 , pp. 355-361
    • Tsunoda, A.1    Nakao, K.2    Watanabe, M.3
  • 89
    • 33749350447 scopus 로고    scopus 로고
    • Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
    • DOI 10.1158/1078-0432.CCR-06-0747
    • Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006;12:5491-5 (Pubitemid 44497265)
    • (2006) Clinical Cancer Research , vol.12 , Issue.18 , pp. 5491-5495
    • Mattison, L.K.1    Fourie, J.2    Desmond, R.A.3    Modak, A.4    Saif, M.W.5    Diasio, R.B.6
  • 90
    • 78049435885 scopus 로고    scopus 로고
    • Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity
    • van Kuilenburg AB, Meijer J, Mul AN, et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010;128:529-38
    • (2010) Hum Genet , vol.128 , pp. 529-538
    • Van Kuilenburg, A.B.1    Meijer, J.2    Mul, A.N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.